Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment
Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterised by loss of motor neurons. The cause of disease is unknown other than in the rare cases of familial disease arising from mutations in the superoxide dismutase 1 gene. Many theories for pathogenesis have been proposed – including oxidative stress, excitotoxicity, mitochondrial dysfunction and abnormal protein aggregation – based on studies of human post mortem tissue, research on animal models, and in vitro work. Here we review the evidence for the main pathogenic mechanisms and outline how they might interact to cause motor neuron death. Clinical trials have as yet failed to identify any truly effective therapies in ALS, with only riluzole providing a modest improvement in survival. Ongoing trials are exploring the value of antiglutamatergic agents, including the cephalosporin antibiotic ceftriaxone, as well as antioxidants, mitochondrial enhancers and anti-apoptotic drugs. It is likely that effective therapy will involve combinations of agents acting on different mechanisms. Gene therapy with neurotrophic factors will soon be in clinical trials, while work on stem cell therapy remains preclinical. In addition to finding effective therapies, research also needs to identify early disease markers because therapy is likely to be of most benefit when given early in the course of disease.
1-22
Goodall, Emily F.
b1af5241-f788-44b5-966c-510db4ca24ef
Morrison, Karen E.
f00890f0-2fde-4dbd-a73b-7422e1b0ede8
Goodall, Emily F.
b1af5241-f788-44b5-966c-510db4ca24ef
Morrison, Karen E.
f00890f0-2fde-4dbd-a73b-7422e1b0ede8
Goodall, Emily F. and Morrison, Karen E.
(2006)
Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment.
Expert Reviews in Molecular Medicine, 8 (11), .
(doi:10.1017/S1462399406010854).
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterised by loss of motor neurons. The cause of disease is unknown other than in the rare cases of familial disease arising from mutations in the superoxide dismutase 1 gene. Many theories for pathogenesis have been proposed – including oxidative stress, excitotoxicity, mitochondrial dysfunction and abnormal protein aggregation – based on studies of human post mortem tissue, research on animal models, and in vitro work. Here we review the evidence for the main pathogenic mechanisms and outline how they might interact to cause motor neuron death. Clinical trials have as yet failed to identify any truly effective therapies in ALS, with only riluzole providing a modest improvement in survival. Ongoing trials are exploring the value of antiglutamatergic agents, including the cephalosporin antibiotic ceftriaxone, as well as antioxidants, mitochondrial enhancers and anti-apoptotic drugs. It is likely that effective therapy will involve combinations of agents acting on different mechanisms. Gene therapy with neurotrophic factors will soon be in clinical trials, while work on stem cell therapy remains preclinical. In addition to finding effective therapies, research also needs to identify early disease markers because therapy is likely to be of most benefit when given early in the course of disease.
This record has no associated files available for download.
More information
e-pub ahead of print date: 24 March 2006
Organisations:
Medical Education
Identifiers
Local EPrints ID: 398837
URI: http://eprints.soton.ac.uk/id/eprint/398837
ISSN: 1462-3994
PURE UUID: 7d930f3c-2778-4780-8e43-c7c20d9c426d
Catalogue record
Date deposited: 02 Aug 2016 12:19
Last modified: 15 Mar 2024 01:43
Export record
Altmetrics
Contributors
Author:
Emily F. Goodall
Author:
Karen E. Morrison
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics